II. Definitions
- Dyspepsia
- Chronic or recurrent Epigastric Pain, burning, early satiety or post-prandial fullness
- Functional Dyspepsia
- At least 1 month of Dyspepsia without underlying organic cause on upper endoscopy OR
- Dyspepsia for at least 3 months of the last 6 months with no signs of organic cause
III. Epidemiology
- Dyspepsia overall Prevalence: 30% of adults in U.S (with 70% of cases Functional Dyspepsia)
IV. Pathophysiology: Functional Dyspepsia
- Unclear etiology, however may be related to altered gastric motility (present in 70-80% of cases)
- Inflammatory and immune factors may also play a role
- Helicobacter Pylori often found in patients with Dyspepsia, but causality is not clear
V. Causes
VI. Symptoms
- Epigastric burning, pain or discomfort
- Early satiety
- Associated symptoms
- Abdominal Bloating (difficult to treat)
- Belching and Flatulence
- Nausea and Vomiting
- Halitosis
VII. Diagnosis: Rome IV Criteria for Functional Dyspepsia
- Symptoms for at least 3 months of the last 6 months
- No evidence for structural disease (including on upper endoscopy if performed) that could explain symptoms and
- Symptom criteria (at least one is present)
- Epigastric Pain or epigastric burning on at least 1 day per week
- Early satiety on at least 1 day per week
- Postprandial fullness on at least 3 days per week
- References
VIII. Associated Conditions: Functional Dyspepsia
- Mood Disorders (e.g. Anxiety Disorder, Major Depression)
- Gastroesophageal Reflux disease (up to 50% co-occurrence)
- Irritable Bowel Syndrome (up to 35% co-occurrence)
IX. Differential Diagnosis
- See Dyspepsia Causes
- See Medication Causes of Dyspepsia
- Functional Dyspepsia diagnosis assumes exclusion of organic cause
X. Approach: Step 1 - Consider differential Diagnosis
- See Dyspepsia Causes
- See Medication Causes of Dyspepsia
- Most common conditions in differential diagnosis
- Idiopathic (functional disorder) in 60% of cases
- Gastroesophageal Reflux disease (often comorbid)
- Peptic Ulcer Disease
- Pancreatitis
- Biliary pain (Cholelithiasis)
- Irritable Bowel Syndrome
- Symptoms relieved by Defecation
- Associated with change in stool frequency or form
- Consider serious underlying causes (e.g. malignancy, Acute Coronary Syndrome)
- Symptomatic therapy in the Emergency Department
- Antacid monotherapy (e.g. Maalox, Mylanta)
- As effective with less side effects than Lidocaine solutions ("GI Cocktail")
- Warren (2020) Acad Emerg Med 27(9): 905-9 +PMID: 32602148 [PubMed]
- Antacid monotherapy (e.g. Maalox, Mylanta)
- General Measures
XI. Approach: Step 2 - Upper Endoscopy for high risk patients
- See Dyspepsia Red Flags for Indications
- Perform early upper endoscopy for those with age >60 years with at least one month of symptoms
- Early endoscopy indications at younger ages (<60 years old)
- High risk groups (e.g. southeast asian descent)
- Use clinical judgment in referral (e.g. multiple red flag symptoms)
- Multiple Dyspepsia Red Flags
- A single isolated red flag in those under age cut-off only mildly increase risk
XII. Approach: Step 3 - Consider Helicobacter Pylori testing
- Indications
- Indicated BEFORE acid suppression therapy in patients under age 60 years old
- Lack of relief with empiric antisecretory therapy
- Undifferentiated Dyspepsia
- H. pylori treatment (when testing positive) does appear effective in Functional Dyspepsia
- Test and treat strategy (without endoscopy) is cost effective
- Reserve endoscopy for Dyspepsia Red Flags (see Dyspepsia Red Flags)
- Dyspepsia Red Flags include age >55 years old, Unexplained Weight Loss, Dysphagia
- Testing
- Protocol
- Treat with H. Pylori Management if positive
- Retest for cure if symptoms persist after treatment
XIII. Approach: Step 4 - Consider empiric antisecretory therapy (acid suppression)
- Timing
- Initial trial for 8 weeks
- Longterm antisecretory use is often needed
- Antisecretory Agents
- Proton Pump Inhibitor (e.g. Omeprazole)
- No advantage to high Proton Pump Inhibitor doses (e.g. double doses)
- Highly effective agents but at higher cost, and with increased risk
- Considered first-line (preferred agents) in Functional Dyspepsia
- Risk of C. difficile, Pneumonia, Osteoporosis, Chronic Kidney Disease with PPI use >12 months
- Meineche-Schmidt (2004) Am J Gastroenterol 99:1050 [PubMed]
- H2 Blocker (e.g. Ranitidine)
- Cost effective initial trial
- Some protocols recommend as initial agent and switching to Proton Pump Inhibitor if not effective
- Proton Pump Inhibitor (e.g. Omeprazole)
- Adjunctive medication options
- Metoclopramide (prokinetic agent)
- May offer benefit in Nonulcer Dyspepsia
- Risk of tardive diskinesia
- Metoclopramide (prokinetic agent)
- Ineffective Medications (avoid)
- Sucralfate offers no benefit in Nonulcer Dyspepsia
- Misoprostol offers no benefit in Nonulcer Dyspepsia
- Bismuth Subsalicylate is not recommended due to toxicity with longerterm use
XIV. Approach: Step 5 - Upper Endoscopy Indications (if not already done above)
- Incomplete relief with above management
XV. Approach: Step 6 - Alternative Therapies
-
Tricyclic Antidepressants
- Amitriptyline (Elavil) titrated to 25 mg nightly (may titrate to 75 mg nightly)
- Imipramine 50 mg nightly
- Ford (2017) Gut 66(3): 411-20 [PubMed]
- Other mental health agents and methods have not been shown consistently effective
- Selective Serotonin Reuptake Inhibitors (SSRI) have NOT shown benefit in Functional Dyspepsia
- Psychotherapy has not shown consistent benefit in Functional Dyspepsia
- Complimentary and Alternative Medicine (possibly effective agents in Functional Dyspepsia)
- Peppermint plus Caraway Oil
- Turmeric (Curcuma longa)
- Iberogast (STW 5)
- Rikkunshito (per American College Gastroenterology)
- Baez (2023) Cochrane Database Syst Rev (6): CD013323 [PubMed]
XVI. References
- Bazaldua (1999) Am Fam Physician 60(6):1773-84 [PubMed]
- Dickerson (2004) Am Fam Physician 70:107-14 [PubMed]
- Fisher (1998) N Engl J Med 339:1376-81 [PubMed]
- Laine (2001) An Intern Med 134:361-9 [PubMed]
- Loyd (2011) Am Fam Physician 83(5): 547-52 [PubMed]
- Moayyedi (2017) Am J Gastroenterol 112(7): 988-1013 [PubMed]
- Mounsey (2020) Am Fam Physician 101(2): 84-8 [PubMed]
- Richter (1991) Scand J Gastroenterol 182:11-6 [PubMed]
- Talley (2005) Am J Gastroenterol 10:2324-37 [PubMed]